Clinical Trial

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 4 changes
notable Trial sites expanded: 5 -> 10 locations 2026-07-24
critical Recruitment opened 2026-05-21
notable Primary completion pushed: 2027-05-27 -> 2028-01-30 2026-05-21
minor Completion pushed: 2029-11-24 -> 2030-07-30 2026-05-21
Trial Details
NCT Number NCT07493512
Lead Sponsor Amgen
Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment 40 participants
Start Date 2026-04-28
Primary Completion 2028-01-30 (estimated)
Study Completion 2030-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07